Page 5 - Small Pharma News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

As the medicinal use of psychedelics gains mainstream attention, fears remain over their effect on mental health and the need for safe administration

Small Pharma Inc. (OTCMKTS:DMTTF – Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 272,300 shares, a growth of 79.6% from the June 30th total of 151,600 shares. Based on an average daily trading volume, of 212,800 […]

• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023

Small Pharma Inc. (OTCMKTS:DMTTF – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 151,600 shares, an increase of 60.1% from the June 15th total of 94,700 shares. Based on an average daily trading volume, of 138,400 […]

Small Pharma Inc. (OTCMKTS:DMTTF – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 151,600 shares, an increase of 60.1% from the June 15th total of 94,700 shares. Based on an average daily volume of 138,400 shares, […]

Leading healthcare intelligence organisation most awarded CRO in 2023 CRO Leadership AwardsDUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading CRO...

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused...

• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile  • Proof-of-concept data from...

Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to